Slide 1: EYP-1901 in wet AMD DAVIO 2 Phase 2 Clinical Trial Topline Data
EYP-1901 in wet AMD DAVIO 2 Phase 2 Clinical Trial Topline Data December 4, 2023 ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially i
Slide 3: Pipeline represents potentially substantial opportunities using Durasert E IVT delivery technology
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. IVT, intravitreal injection Pipeline represents potentially substantial opportunities using our bioerodible Durasert E™ IVT delivery technology EYP-1901 – vorolanib, a selective and patented TKI Positive topline Phase 2 data in wet AMD Phase
Slide 4: EYP-1901 (vorolanib in Durasert E) a potential treatment for wet AMD
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. EYP-1901 (vorolanib in Durasert E) a potential treatment for wet AMD featuring sustained delivery for 6-months or longer
Slide 5: Significant Need for More Durable Therapies in Wet AMD
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. There is a Significant Need for More Durable Therapies in Wet AMD Many patients with wet AMD are chronically undertreated >80% of Retina Specialists say undertreatment is due to patient noncompliance, scheduling limitations or provider prefer
Slide 6: Vorolanib Brings a Potential New MOA to Treatment of VEGF-Mediated Retinal Diseases
Vorolanib Brings a Potential New MOA to the Treatment of VEGF-Mediated Retinal Diseases by Blocking all Isoforms of VEFG and PDGF ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. SoC, standard of care; ANG, angiopoietin; PDGF(R), platelet-derived growth factor (receptor); PLGF, placental gr
Slide 7: Safe Sustained IVT Drug Delivery
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Safe Sustained IVT Drug Delivery Delivered by a single in-office IVT injection Continuous, stable release of drug Zero-order kinetics Durasert®: non-erodible Drug embedded within a bioerodible matrix coated with non-erodible polyimide shell:
Slide 8: EYP-1901: Receptor Binding Vorolanib in Bioerodible Durasert E
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Each insert ~1/5000 of vitreous volume Delivered in the physician office via standard intravitreal injection technique Immediately bioavailable featuring an initial burst of drug followed by zero order kinetics release for ~9 months Positive
Slide 9: The DAVIO Clinical Trial – Background
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. The DAVIO 2 Clinical Trial – Background A non-inferiority trial evaluating two doses of EYP-1901 against an aflibercept control in wet AMD The DAVIO 2 clinical trial was designed to evaluate EYP-1901 in wet AMD and support Phase 3 clinical tr
Slide 10: DAVIO Clinical Trial is Randomized, Double-Masked, Aflibercept Controlled
DAVIO 2 Clinical Trial is Randomized, Double-Masked, Aflibercept Controlled* with a Single EYP-1901 Treatment at Two Doses ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. -D14 to -D7 D1 W4 W8 W12 W16 W24 W32 W36 to W56 W20 W28 EYP-1901 2mg low dose n=53 EYP-1901 3mg high dose n=54 Afliberc
Slide 11: DAVIO Baseline Characteristics Well Balanced Across Arms
DAVIO 2 Baseline Characteristics Well Balanced Across Arms ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Aflibercept 2mg q8W (n=54) EYP-1901 2mg (n=50) EYP-1901 3mg (n=52) Mean age, years (range) 75.9 (52-93) 76.4 (61-93) 75.4 (56-89) Female, % 53.7% 64.0% 67.3% Mean BCVA, ETDRS letters
Slide 12: Phase 2 DAVIO Clinical Trial Topline Results
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 DAVIO 2 Clinical Trial Topline Results A NON-INFERIORITY TRIAL VERSUS AN AFLIBERCEPT CONTROL
Slide 13: EYP-1901 Phase 2 DAVIO Clinical Trial Met All Objectives
EYP-1901 Phase 2 DAVIO 2 Clinical Trial Met All Objectives ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS Met ALL Secondary Endpoints ~80% reduction in treatment burden at 6-months Nearly two-thirds of eyes supplement-free up to six-months Strong
Slide 14: DAVIO Achieved Primary Endpoint of Non-Inferiority in Visual Acuity
DAVIO 2 Achieved Primary Endpoint of Non-Inferiority Change in Visual Acuity in Both EYP-1901 Arms; Statistically and Numerically Non-Inferior to Control (95% CI) ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *Blended week 28 and week 32 NI, Non-inferior; CI, Confidence Interval PRELIMIN
Slide 15: EYP-1901 Statistically Non-Inferior in Change in BCVA Compared to Aflibercept Control
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. +0.9 +1.0 +1.3 *Blended week 28 and week 32 change vs. baseline CI, Confidence Interval PRELIMINARY DATA – PENDING FINAL ANALYSIS EYP-1901 was Statistically Non-Inferior in Change in BCVA Compared to the Aflibercept Control (95% CI) MEAN CHAN
Slide 16: EYP-1901 Demonstrated a Favorable Safety Profile in Phase 2 DAVIO 2 Trial
EYP-1901 Demonstrated a Favorable Safety Profile in the Phase 2 DAVIO 2 Trial (Data Cut as of November 7, 2023) ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. SAE, serious adverse event; AE, adverse event; IVT, intravitreal injection PRELIMINARY DATA – PENDING FINAL ANALYSIS 1- As determi
Slide 17: Clinically Meaningful Reduction in Treatment Burden Supports EYP-1901 as Maintenance Treatment
Clinically Meaningful Reduction in Treatment Burden Supports EYP-1901 as a Maintenance Treatment For Wet AMD ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *Normalized PRELIMINARY DATA – PENDING FINAL ANALYSIS EYP-1901 2mg EYP-1901 3mg Mean number of injections week 8 through week 32 0.55
Slide 18: Significant Reduction in Treatment Burden vs. Aflibercept Control Arm
EYP-1901 Demonstrated a Significant Reduction in Treatment Burden vs. the Aflibercept Control Arm ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS. EYP-1901 2mg EYP-1901 3mg Aflibercept 2mg q8W Mean number of injections week 8 through week 32 0.55 0
Slide 19: EYP-1901 Demonstrated Clinically Meaningful Supplement-Free Rates
EYP-1901 Demonstrated Clinically Meaningful Supplement-Free Rates ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS EYP-1901 2MG EYP-1901 3mg Supplement-Free Rates 65% 64% Percent of Patients Supplement-Free up to Six Months After Administration of E
Slide 20: Nearly Two-Thirds of Eyes Supplement-Free up to Six Months After Single Injection
Nearly Two-Thirds of Eyes Treated with EYP-1901 were Supplement-Free up to Six Months After a Single Injection ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *First visit patients are eligible to be rescued PRELIMINARY DATA – PENDING FINAL ANALYSIS 100% Summary of Supplement-Free Rates by
Slide 21: Stable Anatomy via OCT in EYP-1901 Arms
Stable Anatomy via OCT in EYP-1901 Arms EYP-1901 2mg EYP-1901 3mg Aflibercept 2mg q8W Baseline CST (mean) 262.9 267.0 265.7 Change in OCT at Week 32 vs. Baseline + 15.1 microns + 10.6 microns + 5.4 microns Difference vs. Aflibercept Control + 9.7 microns + 5.2 microns NA ©2023 EyePoint Pharmaceutica
Slide 22: Strong Anatomic Control with OCT Change Below 10 microns at Week 32
Data from DAVIO 2 Suggests Strong Anatomic Control with OCT Change Below 10 microns at Week 32 Compared to the Aflibercept Control ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS MEAN CHANGE in CST +10.6 um +15.1 um +5.4 um EYP-1901 2mg + 9.7 um EY
Slide 23: EYP-1901 Phase 2 DAVIO Clinical Trial Met All Objectives
EYP-1901 Phase 2 DAVIO 2 Clinical Trial Met All Objectives ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS Met ALL Secondary Endpoints ~80% reduction in treatment burden at 6-months Nearly two-thirds of eyes supplement-free up to six-months Strong
Slide 24: EYP-1901 Phase 2 DAVIO Clinical Trial Met All Primary and Secondary Endpoints
EYP-1901 Phase 2 DAVIO 2 Clinical Trial Met All Primary and Secondary Endpoints ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *vs. mean number of injections normalized 6 months prior to screening PRELIMINARY DATA – PENDING FINAL ANALYSIS Endpoint DAVIO 2 Topline DAVIO 2 Lower Limit (as i
Slide 25: EYP-1901 in wet AMD DAVIO 2 Phase 2 Clinical Trial Topline Data
EYP-1901 in wet AMD DAVIO 2 Phase 2 Clinical Trial Topline Data December 4, 2023 ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved.